Immunohistochemical Analysis of Programmed Death-Ligand 1 Expression in Equine Sarcoids.

This research aimed to examine the existence of a specific immune system inhibitor, PD-L1, within equine sarcoids (ES) – a common skin tumor in horses. However, the study concluded that this immune inhibitor had no significant role in ES and therefore does not contribute to developing PD-1/PD-L1-focused immunotherapy for this condition.

Objective of the Study

• The main goal of this research was to analyze the expression of PD-L1, an immune checkpoint inhibitor in equine sarcoids (ES). Equine sarcoids are frequent skin tumors found in horses.

PD-L1 and Its Role in Cancer

• The programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that is often expressed by various cancer cells. These cells use PD-L1 to block T cell-mediated elimination of tumor cells and avoid the immune response.
• Over the years, PD-L1/PD-1 pathway blockade has emerged as an effective therapeutic strategy for various human malignancies, leading to the hypothesis that similar mechanisms might be functional in equine tumors.

Methodology of the Study

• To validate this theory, the researchers tested antibodies specifically targeting human PD-L1 for their capacity to interact (cross-react) with PD-L1 in horses. The testing was performed via immunohistochemistry, a method used to visually localize specific antigens in tissues, using formalin-fixed, paraffin-embedded tissues.

Results and their Implications

• Despite their hypothesis, the research failed to support the substantial role of PD-L1-mediated immune evasion in ES disease, thereby disputing the possibility of employing PD-L1 as a targeted treatment for equine sarcoids.
• This conclusion implies that therapies based on PD-1/PD-L1 blockade, effective in certain types of human cancer, may not be applicable for ES. The absence of substantial PD-L1 expression in sarcoids makes it an unlikely target for immunotherapy in horses.